Stahl A, et al. - Researchers probed into the lower doses of anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab, a substance with a considerably shorter systemic half-life than the standard treatment, bevacizumab in retinopathy of prematurity (ROP). The efficacy of ranibizumab in controlling acute ROP was revealed in this study. It was also determined that 24% of the standard adult dose (0.12 mg) was equally effective as 40% (0.20 mg). As per the outcomes, superior vascularization of the peripheral retina with 0.12 mg of ranibizumab pointed out that lower dose could be favorable. A limited systemic drug exposure after ranibizumab was indicated via unchanged plasma VEGF levels.